These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25849602)

  • 21. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
    Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
    J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Appropriateness Criteria for Active Surveillance of Prostate Cancer.
    Cher ML; Dhir A; Auffenberg GB; Linsell S; Gao Y; Rosenberg B; Jafri SM; Klotz L; Miller DC; Ghani KR; Bernstein SJ; Montie JE; Lane BR;
    J Urol; 2017 Jan; 197(1):67-74. PubMed ID: 27422298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gleason inflation 1998-2011: a registry study of 97,168 men.
    Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
    BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
    Reese AC; Landis P; Han M; Epstein JI; Carter HB
    J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men.
    de Carvalho TM; Heijnsdijk EA; de Koning HJ
    Int J Cancer; 2016 May; 138(10):2522-8. PubMed ID: 26695380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
    BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
    Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
    Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.
    Tosoian JJ; JohnBull E; Trock BJ; Landis P; Epstein JI; Partin AW; Walsh PC; Carter HB
    J Urol; 2013 Oct; 190(4):1218-22. PubMed ID: 23643603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance.
    Monfared S; Fleishman A; Korets R; Chang P; Wagner A; Bubley G; Kaplan I; Olumi AF; Gershman B
    Urol Oncol; 2021 Nov; 39(11):783.e21-783.e30. PubMed ID: 33992521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
    Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
    Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens.
    Djavan B; Kadesky K; Klopukh B; Marberger M; Roehrborn CG
    Eur Urol; 1998; 33(3):261-70. PubMed ID: 9555550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
    Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
    World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Stewart ST; Bhatnagar V; Sweeney CJ; Stahl JE; McMahon PM
    JAMA; 2010 Dec; 304(21):2373-80. PubMed ID: 21119084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment.
    van den Bergh R; Gandaglia G; Tilki D; Borgmann H; Ost P; Surcel C; Valerio M; Sooriakumaran P; Salomon L; Briganti A; Graefen M; van der Poel H; de la Taille A; Montorsi F; Ploussard G;
    Eur Urol Focus; 2019 Mar; 5(2):171-178. PubMed ID: 28801241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study.
    Kasperzyk JL; Shappley WV; Kenfield SA; Mucci LA; Kurth T; Ma J; Stampfer MJ; Sanda MG
    J Urol; 2011 Nov; 186(5):1862-7. PubMed ID: 21944095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.